Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04NIZ
|
|||
| Former ID |
DNCL003081
|
|||
| Drug Name |
AMG 747
|
|||
| Indication | Schizophrenia [ICD-11: 6A20] | Phase 2 | [1] | |
| Company |
Amgen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glycine transporter GlyT-1 (SLC6A9) | Target Info | Modulator | [2] |
| Reactome | Na+/Cl- dependent neurotransmitter transporters | |||
| WikiPathways | NRF2 pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01568216) 20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms. U.S. National Institutes of Health. | |||
| REF 2 | Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discov. 2013 Nov;12(11):866-85. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.